Chronic administration of the probiotic kefir improves the endothelial function in spontaneously hypertensive rats by unknown
Friques et al. J Transl Med  (2015) 13:390 
DOI 10.1186/s12967-015-0759-7
RESEARCH
Chronic administration of the probiotic 
kefir improves the endothelial function 
in spontaneously hypertensive rats
Andreia G. F. Friques1, Clarisse M. Arpini1, Ieda C. Kalil1, Agata L. Gava2, Marcos A. Leal3, Marcella L. Porto3,5, 
Breno V. Nogueira4, Ananda T. Dias3, Tadeu U. Andrade1, Thiago Melo C. Pereira1,5, Silvana S. Meyrelles3, 
Bianca P. Campagnaro1 and Elisardo C. Vasquez1,3*
Abstract 
Background: The beverage obtained by fermentation of milk with kefir grains, a complex matrix containing acid 
bacteria and yeasts, has been shown to have beneficial effects in various diseases. However, its effects on hyperten-
sion and endothelial dysfunction are not yet clear. In this study, we evaluated the effects of kefir on endothelial cells 
and vascular responsiveness in spontaneously hypertensive rats (SHR).
Methods: SHR were treated with kefir (0.3 mL/100 g body weight) for 7, 15, 30 and 60 days and compared with non-treated 
SHR and with normotensive Wistar-Kyoto rats. Vascular endothelial function was evaluated in aortic rings through the relaxa-
tion response to acetylcholine (ACh). The balance between reactive oxygen species (ROS) and nitric oxide (NO) synthase was 
evaluated through specific blockers in the ACh-induced responses and through flow cytometry in vascular tissue.
Results: Significant effects of kefir were observed only after treatment for 60 days. The high blood pressure and 
tachycardia exhibited by the SHR were attenuated by approximately 15 % in the SHR-kefir group. The impaired ACh-
induced relaxation of the aortic rings observed in the SHR (37 ± 4 %, compared to the Wistar rats: 74 ± 5 %), was 
significantly attenuated in the SHR group chronically treated with kefir (52 ± 4 %). The difference in the area under the 
curve between before and after the NADPH oxidase blockade or NO synthase blockade of aortic rings from SHR were 
of approximately +90 and −60 %, respectively, when compared with Wistar rats. In the aortic rings from the SHR-kefir 
group, these values were reduced to +50 and −40 %, respectively. Flow cytometric analysis of aortic endothelial cells 
revealed increased ROS production and decreased NO bioavailability in the SHR, which were significantly attenu-
ated by the treatment with kefir. Scanning electronic microscopy showed vascular endothelial surface injury in SHR, 
which was partially protected following administration of kefir for 60 days. In addition, the recruitment of endothelial 
progenitor cells was decreased in the non-treated SHR and partially restored by kefir treatment.
Conclusions: Kefir treatment for 60 days was able to improve the endothelial function in SHR by partially restoring 
the ROS/NO imbalance and the endothelial architecture due to endothelial progenitor cells recruitment.
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Background
Endothelial cells play a central role in the maintenance 
of the vascular homeostasis and endothelial dysfunction 
has been considered to be an important characteris-
tic that accompanies states of metabolic diseases and 
arterial hypertension [1–4]. Most of the studies related 
to endothelial dysfunction have been performed with 
spontaneously hypertensive rats (SHR), which exhibit 
impaired endothelium-dependent relaxation attribut-
able to excessive generation of NADPH oxidase-driven 
reactive oxygen species (ROS) and decreased nitric oxide 
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(NO) bioavailability [5, 6]. Thus, SHR have been used as 
an important tool for the understanding of hypertension 
and endothelial dysfunction as well as for the identifica-
tion of alternative or non-pharmacological agents for 
prevention/treatment of these diseases.
Previous studies have demonstrated the beneficial 
effects of functional foods, which exhibit several health 
promoting properties in experimental and clinical car-
diovascular studies [7], including the decrease in blood 
pressure in mildly hypertensive subjects [8] and SHR 
chronically treated with these products [9]. Among 
the varieties of scientifically validated functional foods 
available, an important focus of the investigations have 
been fermented milks containing lactic acid bacteria, 
the so-called probiotics, including kefir. The alleged 
health-promoting characteristics of kefir have been 
reviewed [10]. This food product originated in the 
Northern Caucasus has been distributed worldwide. 
While in some countries kefir is already commercially 
available [11], in our country, this probiotic has tradi-
tionally been distributed person-to-person and it has 
been domestically produced by using kefir grains as a 
starter [12]. Milk fermentation with kefir grains forms 
a matrix made up of polysaccharides and proteins pri-
marily produced by the lactic acid bacteria and yeast 
species, which are a complex microbial symbiotic rela-
tionship [13] that results in the production of biogenic 
elements [12, 13].
The effects of isolated microorganisms from probiot-
ics on blood pressure in hypertensive subjects [14] and in 
experimental models of hypertension [15, 16] have been 
investigated. Some studies have investigated their effects 
on the endothelial dysfunction that accompanies arte-
rial hypertension and other cardiovascular diseases [16]. 
However, the effects of the beverage obtained by fermen-
tation of milk with kefir grains, on the endothelial dys-
function observe in the context of hypertension have not 
yet been investigated.
Therefore, our study was designed to test the hypoth-
esis that chronic treatment with kefir may have beneficial 
effects on high blood pressure and endothelial dysfunc-
tion in SHR, a classical model for essential hypertension. 
The importance of the present study is highlighted by the 
fact that it evaluated the effects of kefir grains, which con-
tain a relatively stable and specific microbiota enclosed in 
a matrix of polysaccharides and proteins [17]. The pre-
sent data revealed new insights on the time-dependent 
actions of kefir on functional and structural endothelial 
abnormalities. The findings of the present study included 
the beneficial effects of kefir on the imbalance between 
ROS production and NO bioavailability and the recruit-
ment of endothelial progenitor cells (EPC) to repair the 
damage to the endothelial surface layer in the SHR.
Methods
Animals
The present study was performed in male 4-month-
old SHR and in age-matched Wistar-Kyoto rats, both of 
which were maintained in the animal care facility of the 
Federal University of Espirito Santo, Brazil. The rats were 
acclimatized and housed in individual plastic cages with 
a controlled temperature (22–23 °C) and light–dark cycle 
(12:12 h) and were fed with a standard rat chow and pro-
vided with water ad  libitum. The study protocols were 
approved by the Institutional Committee on Animal Care 
(CEUA, Protocol #040/2014). All experimental proce-
dures were performed in accordance with the guidelines 
for the care and use of laboratory animals as recom-
mended by the National Institutes of Health (NIH).
Kefir: identification, preparation and administration
The kefir used in the present study was obtained from the 
fermentation of the grains in whole milk, as commonly 
consumed by Brazilian people. The bacteria and yeasts 
were identified by the surface spread technique using 
four different Agar media (Acetobacter, Nurient, MRS 
and Sabouraud) and specific conditions of temperature 
(25, 30 and 37  °C), atmosphere (aerobiosis and anaero-
biosis) and time (24, 48, 96 and 120  h). Subsequently, 
the bacterial isolates were Gram-stained and examined 
for colony and cell appearance and for catalase, oxidase, 
coagulase and bile-esculin activity. After isolation of the 
strains, the species were confirmed by using the API gal-
leries (BioMérieux, France).
The kefir beverage was prepared by adding kefir grains 
to pasteurized whole milk in a ratio of 4 % (w/v) and kept 
at room temperature. After 24 h, this mixture was filtered 
through a plastic screen and the resultant product was 
refrigerated (averaging 10 °C) to permit yeast growth for 
24 h. At the end of this process, the kefir was aliquoted 
into sterile plastic tubes and stored at −20 °C until use.
One group of the SHR was treated with kefir 
(0.3  mL/100  g body weight, by gavage) and subdivided 
into 4 different groups, according with the duration of the 
treatment, i.e., for 7, 15, 30 and 60 days. The other group 
of SHR was administered whole milk (0.3 mL/100 g body 
weight, pH adjusted to 5.0) for 7–60 days for use as the 
hypertensive controls. The Wistar rats were administered 
whole milk for 7–60 days and were used as normotensive 
control groups.
Instrumentation for hemodynamic measurements
After 7–60 days of kefir administration, the animals were 
intraperitoneally anesthetized with ketamine plus xyla-
zine (91 + 9.1 mg/kg) and a polyethylene catheter (PE 50) 
filled with heparinized saline (40 U/mL) was positioned 
into the inferior aorta through the left femoral artery and 
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exteriorized to the back of the neck. After 48 h, the end 
of the arterial catheter was attached to an external line 
that was attached to a disposable blood pressure trans-
ducer connected to a pressure processor amplifier and a 
data-acquisition system (Biopac Systems, Santa Barbara, 
CA, USA) for measurement of mean arterial pressure 
and heart rate in unrestrained animals after a period of 
30  min of stabilization. The average of three successive 
measurements was taken as the mean arterial pressure 
value.
Analysis of vascular function
Following treatment, the rats were anesthetized as above 
and a midline abdominal incision was performed to 
expose and isolate the thoracic aorta, which was care-
fully cleaned of the adherent connective tissue under a 
light microscope, and cut into 3–4 mm rings. Each aortic 
ring was mounted on stainless steel triangles, suspended 
vertically in tissue chambers containing 5  mL of modi-
fied Krebs buffer (composition in mmol/L: NaCl 119.0, 
NaHCO3 25.0, glucose 11.2, CaCl2 1.6, KCl 4.7, KH2PO4 
1.2, MgSO4 1.2). The aortic rings were then allowed 
to equilibrate at an optimal tension of 1 g for 60 min at 
37 °C and were continuously oxygenated with a mixture 
of 95 % O2 and 5 % CO2. The Krebs solution was replaced 
every 30  min, and the tension on each aortic ring was 
readjusted to 1 g when necessary. The changes in tension 
during the protocol were recorded isometrically using a 
force–displacement transducer connected to a comput-
erized data acquisition system (Biopac Systems Inc.).
The time-course of the endothelium-dependent relaxa-
tion was tested after a washout period of 30  min using 
response curves to cumulative concentrations of ACh 
(10−11 to 10−4.5 mol/L) in aortic rings pre-contracted 
with phenylephrine (PE, 10−6 mol/L). We challenged the 
aortic rings with ACh at those concentrations because, 
in male SHR, concentration of ACh equal or higher than 
10−4 mol/L results in contractions instead of relaxations. 
For each curve, the maximum effect (Rmax; the upper 
plateau of the sigmoidal curve) and the log of the con-
centration of the agonist that produced half of Rmax (log 
EC50) were calculated using nonlinear regression analy-
sis and the sensitivities of the agonists were expressed as 
pEC50 (−log EC50). The vasorelaxation response to ACh 
was expressed as the percentage of vasodilation relative 
to the maximal PE-induced pre-contraction level.
The role of NO in the relaxation response to ACh was 
evaluated through pre-incubation of the aortic rings with 
the non-specific NO synthase (NOS) inhibitor N(G)-
nitro-l-arginine methyl ester (L-NAME, 100  μmol/L) 
for 20 min. The differences in the area under the curves 
(ΔAUC) for the responses of the aortic rings before and 
after the presence of the inhibitor were calculated and 
these results were expressed in arbitrary units (a.u.). In 
a separate set of experiments, the role for ROS in the 
relaxation response to ACh as a function of time was 
evaluated by incubation of the aortic rings with the 
NADPH oxidase inhibitor apocynin (30  μmol/L), which 
was added to the vessel bath 20 min prior to assessing the 
dose–response curves to ACh. The ΔAUC, Rmax and the 
pEC50 were calculated. In a third set of experiments, the 
endothelium-independent relaxation was tested using 
sodium nitroprusside (SNP, 10−10 to 10−5 mol/L), a donor 
of NO. To address the contribution of the basal NO/
cGMP pathway to the relaxation response of the aortic 
rings to ACh in PE-induced pre-constricted aortic rings, 
we evaluated the responses to ACh after inhibition of 
endothelial NO synthase with L-NAME (100 μmol/L).
Scanning electron microscopy
Scanning electron microscopy was performed following 
modified methods as previously described [18]. Briefly, in 
separate subgroups of animals at time-point of 60 days, 
the entire thoracic aorta was carefully removed and dis-
sected free of connective tissue, fixed in 0.1 mol/L Kar-
novsky-cacodylate buffer (solution A; pH 7.2) for 24  h, 
and post-fixed in a solution of 1.0  % osmium tetroxide, 
1.25 % potassium ferrocyanide and 0.2 mol/L cacodylate 
buffer (solution B) for 1 h,. The samples were then washed 
in cacodylate buffer (0.1 mol/L) and ultrapure water and 
cut open, in longitudinal sections under a stereomicro-
scope, dehydrated in ascending grades of ethanol, and 
critical-point dried with liquid CO2. The specimens were 
mounted on stubs sputter coated with 10  nm of pure 
gold and examined using a scanning electron microscope 
(Jeol, JEM6610 LV, Jeol Inc., USA). For each specimen, 
four photomicrographs were randomly taken at ×  1000 
and × 3000 magnification.
Brazilian kefir grains were also analyzed by scanning 
electron microscopy, as previously described by Magal-
hães et  al. [12]. Briefly, after the preparation of kefir, 
the grains were fixed in Solution A for 48  h, post-fixed 
in Solution B for 1 h, dehydrated in ascending grades of 
ethanol, critical-point dried and coated with gold. The 
preparations were observed using the scanning electron 
microscopy.
Flow cytometry analysis of endothelial cells
Flow cytometry was performed using a FACS Canto II 
(Becton–Dickinson, BD, CA, USA) instrument to quan-
tify the endothelial cells and analyze the intracytoplasmic 
ROS content. For endothelial cell counting, the animals 
were anesthetized as above and the aortic arch was iso-
lated, minced and digested using type II collagenase 
(1000 U/mL, at 37  °C for 60  min at constant shaking). 
The tissue fragments were removed by filtration using 
Page 4 of 16Friques et al. J Transl Med  (2015) 13:390 
a sterile 70-μm nylon mesh. The free cells were imme-
diately washed twice in PBS, to remove the excess col-
lagenase, and the cell suspension was stored at −80  °C. 
The cryovials from each animal were thawed in a 37  °C 
heated orbital shaker and slowly diluted into 5  mL of 
DMEM containing 20 % FBS. The numbers of endothelial 
cells in the aortas were determined using an APC-con-
jugated monoclonal antibody against platelet endothe-
lial cell adhesion molecule (CD31-APC). Briefly, 1 × 105 
cells were re-suspended in PBS and incubated with 5 μL 
of CD31-APC or the respective isotype-matched APC-
conjugated control antibody in the dark (20  min, RT). 
From each sample, 100,000 events were acquired and 
processed using the FACS Diva software (Becton–Dick-
inson, BD, CA, USA).
The intracytoplasmic ROS content was determined 
in isolated endothelial cells, as previously described (3). 
Intracellular •O2−, H2O2, ONOO−/•OH− and NO were 
monitored separately by measuring changes in median 
fluorescence intensity (MFI) emitted by dihydroethidine 
(DHE), dichlorofluorescein (DCF), hydroxyphenyl fluo-
rescein (HPF), and diaminofluorescein (DAF), respec-
tively. Briefly, 106 cells were incubated with 160 mmol/L 
of DHE, 20  mmol/L of DCF, 10  μmol/L of HPF, or 
2  μmol/L of DAF at 37  °C for 30  min (DHE, DCF and 
HPF) or 180  min (DAF) in the dark. The samples were 
then washed, resuspended in PBS and kept on ice until the 
acquisition of 100,000 events by flow cytometry, which 
were subsequently analyzed using FACS Diva software.
Quantification of circulating endothelial progenitor cells 
(EPC)
Flow cytometry was performed to quantify and charac-
terize the phenotypes of the circulating EPC. After col-
lection of whole blood and removal of erythrocytes, the 
samples were purified by negative selection with mono-
clonal antibodies against CD3e (CD3 ε chain), CD11b 
(Integrin αM chain), CD45R/B220, Ly-6G and Ly-6C (Gr-
1), and TER-119/Erythroid Cells (Ly-76) (BD Biosciences, 
San Diego, CA, USA) for 15  min on ice, to deplete the 
lineage committed cells. Subsequently, the cells were 
magnetically labeled, loaded into a BD IMagnet column 
(BD), and the depleted cell fraction (Lin−) was carefully 
collected and analyzed by flow cytometry for quantifi-
cation of the circulating EPC. The cell aliquots (1 × 106 
cells/mL of PBS) were stained for EPC immunopheno-
typing using anti-rat CD117-PECy7 and CD31-APC (BD) 
for 20 min in the dark. From each sample, 100,000 events 
were acquired (FACS Canto II, BD Bioscience) and pro-
cessed using the FACS Diva software (Becton–Dickin-
son, BD, CA, USA). The circulating EPC were defined as 
Lin negative, CD117/CD31- double-positive cells (Lin−/
CD117+/CD31+).
Statistical analysis
The values are expressed as the mean ± S.E.M. Endothe-
lium-dependent and independent smooth muscle vas-
cular relaxation to cumulative concentrations of ACh or 
SNP, respectively, were analyzed by fitting a logistic func-
tion. The maximum effect (Rmax) and the logarithm of 
the molar concentration of the agonist that produced half 
of the Rmax (log EC50) were calculated. The sensitivity to 
ACh or SNP was estimated using the pEC50 (−log EC50). 
The statistical comparisons between the different groups 
were performed by either one-way or two-way analysis of 
variance (ANOVA) for repeated measures or completely 
randomized, followed by Bonferroni’s post hoc test. A 
value of p < 0.05 was considered statistically significant. 
The Statistical analyses were performed using GraphPad 
Prism software version 6.07.
Results
Identification of microbial isolates
The microbiological analysis of random samples of the 
grains used in this study showed that the dominant 
microflora of kefir included various beneficial bacteria 
(Acetobacter aceti, Acetobacter sp., Lactobacillus del-
brueckii delbrueckii, Lactobacillus fermentum, Lactoba-
cillus fructivorans, Enterococcus faecium, Leuconostoc 
spp.), as well as Lactobacillus kefiranofaciens, and yeasts 
(Candida famata, Candida krusei). In another investi-
gation in our laboratory, the microbiological analysis of 
kefir grains revealed that the global counting of microor-
ganisms was 7.5 × 107 CFU/mL.
Microscopy of kefir grains
Figure 1a shows photomicrographs at low magnification 
and without magnification of a sample of the gelatinous 
white kefir grains that were used to ferment the milk in 
our study. Figure  1b–e are representative photomicro-
graphs of kefir grains obtained using scanning electronic 
microscopy showing high-magnifications images of the 
outside (b–d) and inside (e, f ) surface of kefir grains. The 
images generated by scanning electronic microscopy 
show a tightly associated agglomerate of various micro-
organisms around the kefir grains. The exterior surface 
(c, d) shows that the prevalent forms of the microor-
ganisms in the kefir biofilm were short and long curved 
bacilli in tight association with a polysaccharide matrix 
(Fig. 1d). The interior surface suggests that they grow in 
association with the ovoid-shaped yeast cells (Fig. 1e, f ).
Kefir improves blood pressure and heart rate
As expected, the conscious SHR exhibited high lev-
els of mean arterial pressure (ranging from 162 to 
169  mmHg, p  <  0.05) compared with the Wistar rats 
(ranging from 98 to 102 mmHg). Administration of kefir 
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for 7, 15 and 30 days, did not have a significant effect on 
the high blood pressure, but when it was administered 
for 60  days a significant decrease in this parameter was 
observed (145 ± 5 mmHg, p < 0.05). The SHR also exhib-
ited increased resting heart rates (ranging from 376 to 
388 bpm, p < 0.05) compared with the Wistar rats (rang-
ing from 335 to 340  bpm). Administration of kefir to 
SHR for 7, 15 and 30 days did not affect this parameter 
(Fig. 2b), but after 60 days, it caused a significant decrease 
in the heart rate of the SHR group (332  ±  15  bpm, 
p < 0.05).
Beneficial effects of kefir on the endothelial dysfunction 
of SHR
Average values of the vascular endothelium-dependent 
ACh-induced relaxations of the aortic rings from all 
groups evaluated are shown as line graphs of Fig.  3. The 
time-course of the concentration-dependent ACh-evoked 
relaxation in aortic rings pre-constricted with PE from the 
normotensive Wistar rats showed a tendency to loss reac-
tivity as indicated by the comparison of the time-points 
7 and 60 days (Rmax: 81 ± 4 and 74 ± 4 %, respectively, 
Fig.  3b). The SHR animals exhibited an impaired relaxa-
tion response to ACh (p  <  0.01) at all time-points. The 
Fig. 1 Photomicrographs of kefir grains obtained at the unmagnified level (a) and scanning electronic micrographs of the exterior (b–d) and 
interior (e, f) surface of a kefir grain. The external surface (c, d) shows the prevalence of the bacilli in tight association with a polysaccharide matrix 
(kefiran). The inside surface shows rod-shaped bacilli growing in association with yeasts (e, f)
Fig. 2 Time-course of the effects of kefir on hemodynamic param-
eters in SHR. The bar graphs show average values (mean ± SEM) of 
the mean arterial pressure (a) and heart rate (b) of SHR treated with 
kefir compared to non-treated SHR and Wistar rats. *p < 0.05 vs. 
Wistar group; #p < 0.05 vs. SHR (two-way ANOVA)
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three parameters of the dose–response curve to ACh in 
the untreated SHR showed Rmax (~37 ± 4 %), sensitivity 
(~6.9 ± 0.2 –log M ACh) and AUC (~101 ± 13 a.u.) sig-
nificantly impaired when compared with the normoten-
sive Wistar rats (~74 ± 4, ~7.9 ± 0.2 % –log M ACh, and 
273 ±  16 a.u, respectively) (Fig.  3a–c). Daily administra-
tion of Kefir to the SHR caused a progressive improvement 
of the vascular responsiveness, reaching significant dif-
ferences after 60 days of treatment, as noted in the Rmax 
(52 ± 4 %, p < 0.05), sensitivity (7.5 ± 0.26 –log M ACh, 
p < 0.05) and AUC (167 ± 10 a.u., p < 0.01) (Fig. 3a–c).
Therefore, the treatment of SHR with kefir for 30 days 
did not result in significant improvement of the ACh-
induced relaxations of aortic rings in  all parameters. 
Interestingly, when the SHR were treated for twice as 
long, significant effects were observed in all parameters 
(AUC, Rmax and pEC50). Although kefir administration 
did not restore the values of these three parameters to 
the same levels observed in normotensive Wistar rats, 
the beneficial effects on the endothelial dysfunction were 
highly significant.
Mechanisms of endothelial dysfunction in the SHR: the role 
of ROS
In a separate set of experiments, we evaluated the contri-
bution of ROS to the impaired endothelium-dependent 
vasodilator response of the aortic rings to ACh by inhib-
iting NADPH oxidase with apocynin. Figure  4a, shows 
the concentration–response curves to ACh with and 
without inhibition of NADPH oxidase by apocynin in 
the 3 groups of animals at the time-point of 60 days. The 
pre-blockade of the aortic rings with apocynin caused a 
minor effect in the vasodilator response to ACh in the 
Wistar normotensive rats as shown in the Rmax (−8 %, 
p > 0.05, Fig. 4c), sensitivity (−9 %, p > 0.05) and ΔAUC 
(10 a.u., p  >  0.05, Fig.  4b). The blockade of the aor-
tic rings with apocynin in the untreated SHR caused a 
marked exacerbation of the vasodilator response to ACh 
(Fig. 4a, middle graph); the Rmax changed from 41 ± 6 to 
72 ± 7 %, p < 0.05, Fig. 4c), which was very close to Rmax 
of the Wistar group (81 ± 6 %). Consequently, the differ-
ence in the AUC was 101 ± 3 a.u. (Fig. 4b, p < 0.05). On 
the other hand, in the group of SHR administered with 
kefir for 60 days, the relaxing response to ACh under the 
blockade of NADPH oxidase with apocynin was not as 
exacerbated as it was in the untreated SHR group (Fig. 4a, 
p  <  0.05); the Rmax changed from 48 ±  4 to 63 ±  5  % 
(Fig. 4c) and the difference in the AUC was 58 ±  4 a.u. 
(Fig. 4b). The above results indicate that the ROS is the 
major contributor to the impaired relaxation response to 
ACh in the SHR and that kefir administration for 60 days 
partially attenuated this condition because the blockade 
Fig. 3 Time-course of the effects of kefir administration on the endothelial dysfunction of SHR. Dose–response curves to acetylcholine-induced 
relaxations of aortic rings from SHR-kefir compared to the non-treated SHR and to the normotensive Wistar rats (a). The bar graphs show the maxi-
mum relaxation (b), the area under the curve (c) and the sensitivity (pEC50, d) to acetylcholine. The values shown are the mean ± SEM. *p < 0.05 vs. 
Wistar group; #p < 0.05 vs. SHR (two-way ANOVA)
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of NADPH oxidase caused additional improvement in 
the endothelial function in SHR with Kefir for 60 days.
Endothelial cell counting and intracytoplasmic ROS 
production in the aortic arch
To test the anti-oxidative properties of this probiotic, we 
used flow cytometry to evaluate the production of the 
three main ROS and to estimate the number of endothe-
lial cells and their NO production in the aortas from 
the Wistar rats age-matched SHR with or without 7, 15, 
30 and 60  days of treatment with kefir. The intracyto-
plasmic ROS content was determined using the probes 
DHE, DCF and HPF to quantify the production of •O2−, 
H2O2, and ONOO−/•OH−, respectively (Fig.  5a–c). 
A tendency for an increase in the production of •O2−, 
H2O2 and ONOO−/•OH− over time was noted, which 
reached maximum values at 60 days in the Wistar group 
(2974  ±  151, 1762  ±  22 and 1317  ±  54 MFI, respec-
tively) with significantly higher values being observed in 
the SHR group (4399 ± 193, 2271 ± 100 and 1702 ± 40, 
respectively). The time-course effects of the kefir showed 
a beneficial effect of this probiotic on the production of 
•O2−, H2O2, and ONOO−/•OH− in the aortas of SHR 
when administered for 60  days. As shown in Fig.  5a–c, 
kefir caused a reduction in the production of •O2− 
(3533  ±  147 MFI, −20  %, p  <  0.01), H2O2 (1933  ±  95 
MFI, −15  %, p  <  0.05) and ONOO−/•OH− (1374 ±  44 
MFI, −20  %, p  <  0.01) compared with the non-treated 
SHR.
The flow cytometry approach was also used to evaluate 
the number of endothelial cells (through CD31-APC) and 
the production of NO (through DAF) in the aortic arch 
Fig. 4 Effects of kefir administration on ROS contribution to the endothelial dysfunction in SHR. Dose–response curves to acetylcholine-induced 
relaxations of aortic rings from SHR-kefir compared to the non-treated SHR and to the normotensive Wistar rats after the pre-blockade with apoc-
ynin (a). The bar graphs show the difference in the area under the curve  (b) and the maximum relaxation (c) in response to acetylcholine. The values 
are the mean ± SEM (n = 7–8 animals per group)
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from the three groups of animals (Fig. 5). The number of 
aortic endothelial cells was similar in the SHR and Wistar 
rats at the time-point of 7 days, but the values declined 
in the SHR and at the time-point of 60 days the number 
of cells was significantly diminished in this group (33 %, 
p  <  0.05) compared with the Wistar rats (12.9  ±  1.3 
CD31-positive cell count). The chronic administration of 
kefir for 60 days to SHR group abolished this difference in 
the number of CD31-positive cells in the aorta (Fig. 5e).
As expected, similar results were observed in the anal-
ysis of NO production in the aortas of the three groups 
of animals. The NO production by the endothelial cells 
isolated from the aortic arch of the SHR was signifi-
cantly diminished (16 %) compared with the Wistar rats 
(1712 ± 86 MFI). Kefir administration for 60 days to SHR 
abolished the difference in the NO production in the aor-
tas from these animals (Fig. 5d).
Mechanisms of endothelial dysfunction in the SHR: the role 
of NOS
To address the mechanisms by which kefir produces 
the beneficial effects on endothelial function, first we 
Fig. 5 Time-course of changes in the ROS content and the number of endothelial cells in the aorta from the hypertensive rats administered kefir. 
The graphs show production of superoxide anion (a), hydrogen peroxide (b), peroxynitrite/hydroxyl radical (c), nitric oxide (d), and the number of 
endothelial cells (e) measured through flow cytometry and comparing SHR-kefir group with non-treated SHR and Wistar rats. The values are the 
mean ± SEM. *p < 0.05 vs. Wistar group; #p < 0.05 vs. SHR (two-way ANOVA)
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investigated the participation of the molecular NO/
cGMP pathway in this process by examining the endothe-
lium-dependent vasodilator response of aortic rings to 
ACh when NOS was inhibited with L-NAME. Figure 6a 
shows the concentration–response curves to ACh in the 
presence and absence of inhibition of the NOS path-
way by L-NAME in the three groups of animals at the 
60-day time-point. Pre-blockade of the aortic rings with 
L-NAME caused a marked reduction in the vasodilator 
response to ACh in the Wistar group, reaching an Rmax 
of 11 ± 1 % (Fig. 6b). The remaining relaxation under the 
blockade of NOS with L-NAME is attributed to the relax-
ing factors of the prostanoids pathway, such as the pros-
tacyclin PGI2. As expected, the untreated SHR exhibited 
a contractile effect in response to ACh (Rmax of approxi-
mately 7 ± 4 %). The administration of kefir to SHR for 
60 days reversed the contraction to a relaxation response 
(Rmax 3 ± 0.1 %) (Fig. 6b). Consequently, the ΔAUC (dif-
ference between before and after L-NAME blockade) 
was greater in the Wistar rats (257 ± 12 a.u.) than in the 
SHR (132 ± 9 a.u., p < 0.05) and kefir administration for 
60 days caused a significant improvement in the ΔAUC 
(174 ± 8 a.u, p < 0.05) (Fig. 6c).
The above results indicate that the NO/cGMP pathway 
is the major contributor to the ACh-induced relaxation 
response in the normotensive Wistar rat. Our data shows 
that in the SHR, this pathway seems to be the unique 
pathway for relaxation and that Kefir administration for 
60  days was able to partially repair this abnormal con-
dition. Figure  6d depicts the quantification of the basal 
NO/cGMP activation estimated through the PE-induced 
contraction of the aortic rings under the conditions of 
pre-blockade with L-NAME. Under these conditions, 
the contraction Rmax was significantly smaller in the 
non-treated SHR than in the normotensive Wistar rats 
(59 ± 9 vs. 97 ± 7 %, p < 0.05). Kefir administration for 
60 days to SHR caused a marked beneficial effect on this 
variable (120 ± 14 %, p < 0.05).
Fig. 6 Contribution of the nitric oxide bioavailability to the endothelial dysfunction in SHR administered kefir for 60 days. The line graph (a) shows 
the changes in the dose–response to acetylcholine following the endothelial NO synthase blockade with N(G)-nitro-l-arginine methyl ester 
(L-NAME). The bar graphs show the average values of the maximum response (b) and the difference in the area under the curve (ΔAUC, c) calculated 
from the dose–response curve obtained during the blockade of the basal NO/cGMP molecular pathway with L-NAME. The bar graph d shows 
the basal NO/cGMP molecular pathway activation, indicated by the phenylephrine-induced contraction of the aortic rings during the setting of 
endothelial NO synthase blockade via L-NAME, comparing the 3 groups of animals. The values are the mean ± SEM (n = 7–8 per group). *p < 0.05 
vs. Wistar group; #p < 0.05 vs. SHR [two-way (a) and one-way (b–d) ANOVA]
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Scanning electron microscopy analysis of vascular 
endothelial layer architecture
Considering the magnitude of the functional damage 
observed through the test of the vascular endothelium-
dependent relaxation to ACh in the SHR, we used some 
animals of each group (n = 4 per group) to evaluate the 
damage to the architecture of the endothelial surface.
En face scanning electron micrographs (Fig.  7) of the 
thoracic aortas from the normotensive Wistar animals 
showed a confluent endothelial cell layer. In contrast, 
those of the SHR exhibit a clear endothelial damage of 
the luminal surface layer exposing the internal elastic 
membrane, in which many gaps were observed. Another 
important finding was that the SHR animals treated with 
kefir for 60 days exhibited an endothelial surface contain-
ing regenerated cells, which partly covered the injured 
intima area; however, some gaps between the cells still 
were observed.
Recruitment of circulating endothelial progenitor cells
Flow cytometric analysis of the EPC was performed 
using the peripheral blood of Wistar, SHR and SHR-kefir 
rats. The time-point of 60  days was selected because of 
the endothelial recovery observed by scanning electron 
microscopy images. The analyses of the data revealed that 
the fraction of CD117+/CD31+  double-positive cells 
in the peripheral blood was significantly reduced in the 
SHR (86 ± 11, cell count), compared with Wistar group 
(207 ± 23 cell count, p < 0.01), and kefir administration 
for 60 days was able to increase the circulating EPC levels 
(134 ± 7 cell count, p < 0.05).
Effects of kefir on the endothelium‑independent 
relaxations
The findings of endothelial dysfunction and damage to 
the endothelial surface in the SHR, led us to evaluate the 
time-course of responsiveness of the smooth muscle cells 
to the NO donor SNP in a separate set of experiments, 
to verify the functional integrity of the smooth muscle 
cells of the aorta and the effects of kefir administration 
on these cells.
The dose–response curves for the aortic ring relaxa-
tion in response to SNP were impaired in the SHR group 
compared to those of the Wistar rats. For instance, at the 
60-day time-point, the SHR group exhibited a smaller 
Rmax and sensitivity (72 ± 3 % and 7.4 ± 0.05 –log M) 
than the Wistar rats (87 ±  5 and 8.0 ±  0.07  % –log M, 
p  <  0.05) (Fig.  8). Our data also showed overlapping 
dose–response curves from the non-treated SHR and 
the SHR treated with the probiotic kefir for 7–60  days, 
i.e., kefir did not cause any effect on the Rmax and or the 
sensitivity of the aortic rings to SNP at any of the time-
points examined.
Discussion
This study was designed to investigate the effects of kefir 
on the endothelial dysfunction in the SHR. Using the 
gold-standard approach to evaluate the vascular reactiv-
ity of aortic rings, we observed an impaired relaxation 
response to ACh in the SHR group, which was mainly 
due to an imbalance in the NOS/ROS pathways and was 
accompanied by damage to the endothelial surface layer. 
The novelty of this study was the demonstration that daily 
Fig. 7 Recovery of vascular endothelial surface architecture in SHR administered with kefir. Scanning electron microscopy showing representative 
endothelial structure of aortas from a normotensive Wistar rat, a non-treated SHR and a SHR treated with kefir for 60 days. Scale bar 10 µm. White 
arrow endothelial cell; white arrow head endothelial surface denudation; black arrow gaps
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administration of the probiotic kefir for 60 days, caused a 
significant improvement of the vascular endothelial func-
tion. Our data also provide a clear demonstration that 
the main mechanism for this beneficial effect of kefir 
involved repair in the vascular endothelial architecture 
and a reduction of the oxidative stress coupled with an 
augmentation of the NO bioavailability as well as a simul-
taneous contribution of EPC recruitment.
Interestingly, our scanning electron microscopy analy-
sis of kefir grains revealed that the majority of the biofilm 
composed of short and long curved bacilli or ovoid-
shaped yeast, consistent with the previous observation of 
Hamet et  al. [19]. Isolates from various traditional Bra-
zilian kefir grains have been identified and characterized 
as consisting of a matrix made up of polysaccharides/
proteins and containing acid bacteria belonging to the 
genuses Leuconostoc spp., Lactococcus spp. and Lacto-
bacillus spp. and yeast [20]. Accordingly, our microbio-
logical analysis of kefir samples showed the presence of 
various beneficial bacteria and yeasts, including the spe-
cific Lactobacillus kefiranofaciens species, which pro-
duces kefiran, the main functional component of the 
beverage [19]. Importantly, in the present study, kefir was 
produced with kefir grains, which is more desirable than 
kefir produced with starter cultures [10].
Several studies have suggested that chronic consump-
tion of bioactive fermented milk products may have a 
protective effect against the development of cardiovas-
cular diseases, including an inversely relationship to the 
risk of hypertension [9] and hyperglycemia [21]. Kefir 
has been shown to decrease blood pressure [16] and 
ischemia–reperfusion injury [11], suggesting that this 
fermented milk beverage can be useful in the medical 
management of various cardiovascular conditions. These 
beneficial effects have been explained by the presence of 
bacteria and yeast that share a close symbiotic relation-
ship in the kefir grains [13] and result in the production 
of biogenic elements [19].
Although several studies have demonstrated chronic 
treatment with bioactive fermented milk products atten-
uates high blood pressure [8, 9], some have specifically 
focused on the effects of the complex kefiran in hyperten-
sive subjects [14] and on experimental models of hyper-
tension [15]. Our present data reveal a new important 
feature of this probiotic in the SHR, the most commonly 
used model, which may allow that generalization of the 
results. For instance, we observed that kefir administra-
tion lowered the high blood pressure and tachycardia of 
SHR in a time-dependent manner, reaching the optimal 
beneficial effects at the time-point of 60  days of treat-
ment. Although arterial hypertension is a multifactorial 
disease, endothelial dysfunction has been considered to 
be an important contributor to and thus a valuable bio-
marker for hypertension and other cardiovascular dis-
eases, highlighting the importance of our analysis of the 
effects and mechanisms of kefir on the aortic rings from 
SHR.
Very few studies have been designed to evaluate the 
beneficial effects of the consumption of fermented milk 
with bioactive components on endothelial dysfunction 
in SHR, and their results indicated opposite effects [9]. 
Our data demonstrated that the endothelium-dependent 
relaxation of aortic rings in response to ACh was signifi-
cantly smaller in the SHR compared with normotensive 
Wistar rats, corroborating some previous studies [22, 23] 
but in disagreement with others [24]. Considering that 
Fig. 8 Time-course effect of the kefir administration on the endothelium-independent relation in SHR. The dose–response curves to the NO donor, 
sodium nitroprusside, of aortic rings from SHR administered kefir compared to the non-treated SHR and to the normotensive Wistar rats (a). The 
values are the mean ± SEM. *p < 0.05 vs. Wistar group (two-way ANOVA)
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our focus was to study the vasodilation process and based 
on the observation by others [23] that very high doses of 
ACh in aortic rings from the SHR induce endothelium-
dependent contractions, the maximal dose of ACh tested 
in the present experiment was less than 10−4 mol/L. In 
addition, our first novel finding consisted of the demon-
stration that kefir administration caused a time-depend-
ent improvement in the endothelial function in SHR, 
very similar the observed improvements in blood pres-
sure and heart rate. Considering the similar time-course 
of the beneficial effects on hypertension and endothelial 
dysfunction, the idea that the improvement of endothe-
lial function may have contributed to the attenuation 
of arterial hypertension in the SHR to which kefir was 
administered seems reasonable.
Experimental genetic models of arterial hypertension 
are characterized by endothelial dysfunction, which is a 
primary contributor to the increased generation of ROS, 
leading to NO breakdown [1, 22, 25]. Therefore, we first 
focused on the contribution of ROS to the endothe-
lial dysfunction observed in the SHR model and on the 
potential of chronic administration of kefir to amelio-
rate this dysfunction. The endothelial dysfunction occurs 
as consequence of an exaggerated production of •O2−, 
which is mainly derived from NADPH oxidase and which 
scavenges NO to form peroxynitrite and consequently 
decreases the NO bioavailability in the vascular endothe-
lium [4, 26]. This explains the enhanced generation of 
NADPH-mediated ROS in the aorta of SHR [27].
Our data showed that the blockade of the main source 
of ROS with apocynin was ineffective in rings from the 
normotensive Wistar rats but significantly improved the 
blunted endothelium-dependent relaxation ACh in aor-
tic rings from the SHR. Our results are in agreement 
with others in showing a relationship between hyper-
tension and oxidative stress and between increased ROS 
production and impaired vascular reactivity [28, 29]. 
Moreover, we had previously demonstrated that thera-
pies that decrease ROS production in endothelial cells 
from hypertensive and atherosclerotic mice result in 
the reestablishment of the vascular function [3, 18, 30]. 
Importantly, in this experiment, the SHR animals that 
were chronically treated with kefir exhibited normalized 
relaxation response to ACh, and also a very small change 
in the dose–response curve to ACh under the apocynin 
blockade, which was comparable to that observed in 
the normotensive Wistar rats. The present data support 
other studies that had demonstrated that kefir treatment 
of rats and humans reduced the risk of developing hyper-
tension-associated complications [31]. Recently, others 
have also observed an improved vascular reactivity asso-
ciated with the reduction of oxidative stress in human 
beings and animals with metabolic disturbances when 
treated with probiotic Lactobacillus [32].
The cumulative data, including those from the present 
study and from other models of experimental hyperten-
sion, are consistent with the concept that oxidative stress 
contributes to cardiovascular complications of hyperten-
sion and endothelial dysfunction and vice versa [3, 18, 
33]. In this context, our hypothesis was that the probi-
otic kefir could reduce oxidative stress and consequently 
increase NO availability in the aortic endothelial cells 
as an additional mechanism, contributing to beneficial 
cardiovascular effects of nutritional therapy. In agree-
ment with the vascular reactivity, the aortic endothelial 
cells from SHR exhibited an excessive production of ROS 
(mainly ONOO−/•OH−) compared with the cells from 
the Wistar rats, which was attenuated by kefir treatment 
for 30 and strongly decreased by treatment for 60 days. 
Importantly, kefir treatment increased NO availabil-
ity and the number of EPC counted by flow cytometry 
in the aortic tissue of SHR, confirming the concept that 
endothelial function is restored by this probiotic. Moreo-
ver, we also used pharmacological approaches to evaluate 
whether kefir could improve the NO/cGMP signaling.
The blockade of NOS with L-NAME markedly reduced 
the relaxation response to ACh of aortic rings from 
Wistar rats (~70 %), indicating that most of the relaxation 
is dependent on this pathway. In contrast, L-NAME abol-
ished the ACh-induce relaxations and evoked concen-
tration-dependent contractions in the non-treated SHR, 
indicating that the reduced (~35 %) relaxation response 
to ACh might be attributed to the NOS pathway. In the 
SHR treated for 60 days with kefir, our data also showed 
that L-NAME completely blocked the improved vasodi-
lation responsiveness, which indicates that the improve-
ment of endothelial function in SHR involved (at least in 
part) the restoration of NO bioavailability. Interestingly, 
our data corroborates recent findings which demonstrate 
that the anti-oxidative properties of kefir involve the acti-
vation of scavenging enzymes and/or decrease expres-
sion/action of other pro-oxidant sources enzymes [34].
It is noteworthy that under the blockade of the NOS 
pathway, ACh still caused a residual vasodilation (~10 %) 
in the Wistar rats and a contraction (~10 %) in the SHR, 
whereas neither significant contraction nor vasodilation 
was observed in the aortic rings from the SHR treated 
with kefir. Thus, the remaining relaxation induced by 
ACh after incubation with L-NAME in Wistar rats could 
be attributed to a vasodilator prostanoid pathway (e.g., 
PGI2). On the other hand, the ACh-induced contractions 
of aortic rings under the L-NAME blockade in SHR could 
be the result of an ACh-induced increase in the lev-
els of vasoconstrictor prostanoids (e.g., endoperoxides, 
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thromboxane A2 and prostaglandin E2), which might 
explain that response [25]. This is also supported by the 
finding that incubation with L-NNA and indomethacin 
together completely prevented the ACh-induced con-
traction in the SHR model [23].
Based on the experimental evidence, it is possible that 
the augmented ROS production (as observed in the SHR) 
could inactivate NO in the endothelial cells, causing both 
endothelial dysfunction and diminishing EPC mobiliza-
tion and function [35]. Thus, an attempt was also made to 
gain insights into the structural changes in the endothe-
lial surface of the aorta. This possibility led us to examine 
the endothelial surface layer using scanning electronic 
microscopy. As expected, in conjunction with our func-
tional data, the substantial re-endothelialization we 
observed in SHR rats treated with kefir for 60 days could 
explain the partial recovery of the architecture surface, 
with a simultaneous increase in endothelial cell counts 
in this group. These observations are consistent with the 
results obtained in the present study with respect to the 
vascular reactivity and in ROS production, suggesting 
that kefir presented a prompt and notable re-endotheli-
alization action. Taken together, so far our results allow 
us to conclude that, chronic treatment of SHR with kefir, 
in addition to the reduction of ROS generation and, sub-
sequently, restoration of the NO availability in the aorta 
also partially repairs the damage to the endothelial sur-
face layer in that group. The increases in the endothelial 
cell count and re-endothelialization in the hypertensive 
rats chronically treated with kefir led us to design a new 
protocol focused on the EPC. On the basis that NO plays 
an important role in the EPC mobilization [36, 37], re-
endothelialization in the SHR chronically treated with 
kefir could be attributed to the increased production of 
NO by the endothelial cells, which could attract EPC to 
the injured artery layer. In addition, it has been previ-
ously demonstrated that hypertensive subjects exhibit 
diminished number of functional circulating EPC [25], 
consistent with our findings in the SHR group. However, 
we demonstrated that SHR rats treated with kefir for 
60 days exhibit a marked increase in the circulating EPC 
numbers.
The interplay between oxidative stress and inflam-
mation directly influence EPC mobilization [35] and 
indirectly lead to endothelial surface denudation [38], 
contributing to the development of hypertension [39], 
consistent with our data in the SHR animals. There is 
evidence that EPC may act on the oxidative stress by 
diminishing deleterious intracytoplasmic ROS and simul-
taneously augmenting NO [36, 37]. In addition, oth-
ers have shown that the increased NO release is due to 
enhanced activity of NO synthase [40] and these effects 
could in turn induce EPC mobilization from the bone 
marrow to the peripheral blood [41]. Once mobilized into 
the peripheral circulation, EPC locate to the injured parts 
of the artery and are involved in the re-endothelialization 
[42–44]. Therefore, the novelty of the present study is 
that kefir chronically administered to SHR resulted in a 
significant increase in the EPC recruitment, which could 
explain, at least in part, the notable reparative effect of 
this beverage on the architecture of the endothelial sur-
face and in the improvement of endothelial function in 
SHR treated with kefir for 60 days. Accordingly, our data 
provide the first evidence that the beneficial effects of 
kefir on the endothelial dysfunction in hypertensive ani-
mals may be linked to the EPC recruitment.
A controversial issue in endothelial dysfunction in the 
SHR model is the functional responsiveness of the vas-
cular smooth muscle cells. Accordingly, impairment of 
the relaxation caused by the direct smooth muscle vaso-
dilator SNP in SHR has been reported by some investiga-
tors [26, 45] but not by others [46]. In the present study, 
the time-course evaluation of aortic rings of the SHRs 
showed significantly smaller relaxation in the SNP than 
those of age-matched Wistar rats, at all time-points. 
These results suggest that arterial hypertension in this 
model is also associated with a defect in smooth muscle 
relaxation. It is noteworthy that kefir treatment even for 
60 days did not significantly affect the endothelium-inde-
pendent relaxation in SHR. This result indicates that the 
beneficial effects we observed of kefir on the endothelial 
dysfunction might be limited to the endothelial surface 
cells.
Conclusions
Taken together, our data provide the first evidence that 
kefir (even at a low dose) was able to attenuate endothe-
lial dysfunction in the large vessels in SHR by decreasing 
intravascular ROS production and consequently restor-
ing intravascular NO availability. Additionally, kefir also 
seems to play a relevant role in the re-endothelialization 
of the vasculature, probably by EPC recruitment and this 
may contribute for the (partial) repair of the vascular 
endothelial architecture in the SHR. Figure 9 summarizes 
the beneficial effects of kefir on the endothelial dysfunc-
tion based on our data in the present study with SHR.
Perspectives
The present data corroborates the idea that kefir could 
be used to design translational plans for treatment and/
or prevention of cardiovascular diseases in which benefi-
cial microorganisms delay the progression of disease. It 
is possible that the beneficial effects of kefir on the oxi-
dative stress of hypertensive animals may be associated 
with some bacteria strains that diminished the levels of 
circulating pro-inflammatory cytokines, suggesting that 
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some specific strain of kefir has antioxidant and anti-
inflammatory properties. Studies performed in animals 
fed with isolated bacteria from kefir grains, such as Lac-
tobacillus kefiranofaciens, which was an important com-
ponent of kefir grains in our study, presented beneficial 
cardiovascular effects in SHR [16, 47]. Therefore, the 
future challenge is to identify components of kefir grains 
to improve endothelial function in cardiovascular dis-
eases, favoring the growing field of development of func-
tional foods.
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